Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells

Area of Science:

• Stem Cell Biology
• Regenerative Medicine
• Cell Therapy

Background:

• Bone marrow is the conventional source for human multipotent mesenchymal stem cells (MSCs).
• The placenta presents a more accessible alternative source for MSC isolation.
• Evaluating placenta-derived MSCs (hpMSCs) against bone marrow-derived MSCs (hbmMSCs) is crucial for clinical applications.

Purpose of the Study:

• To comprehensively compare human placenta-derived MSCs (hpMSCs) and human bone marrow-derived MSCs (hbmMSCs).
• To assess cell characteristics, optimal growth conditions, and in vivo safety of hpMSCs.
• To determine the suitability of hpMSCs for clinical trials.

Main Methods:

• Isolation and ex vivo expansion of MSCs from human placenta (hpMSC) and bone marrow (hbmMSC) under Good Manufacturing Practice (GMP) conditions.
• Comparative analysis of proliferation characteristics, morphology, cell surface phenotype, and mesodermal differentiation potential.
• In vivo safety assessment in mice via intravenous injection and genetic stability analysis using SNP GeneChip.

Main Results:

• hpMSCs and hbmMSCs demonstrated similar proliferation under various culture conditions, but hpMSCs showed superior proliferation at different seeding densities and greater long-term growth.
• Both cell types exhibited comparable morphology, phenotype, and differentiation capacity, with hpMSCs showing slightly reduced adipogenic differentiation.
• No copy number changes were detected in either cell type during passaging, and both showed no acute toxicity in vivo.

Conclusions:

• Human placenta is a suitable alternative source for mesenchymal stem cells (MSCs).
• hpMSCs possess comparable characteristics and safety profiles to hbmMSCs, with enhanced proliferative capacity.
• The findings support the ongoing evaluation of hpMSCs in clinical trials.